Infectious Disease AlertHealth outcomes (AIM-HIGH) trial. Am Heart J. 2011;161:538-43. 23. Kinosian B, Glick H, Garland G. Cholesterol and coronary heartGlobal Health outcomes (AIM-HIGH) trial. Am Heart J 2011; 161:538-543.NHL...
The AIM-HIGH Trial The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial evaluated the impact of extended-release niacin versus placebo in patients with established atherosclerotic disease on statin therapy, with a back...
Safety profile of extended-release niacin in the AIM-HIGH trial. EDS, Sun aim high with partnership National Health Insurance or Incremental Reform: Aim High, or at Our Feet? The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health...
The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Trial: To Believe or Not... ED Michos,CT Sibley,JT Baer,... - 《Journal of the American College of Cardiology》 被引量: 134发表: 2012年 The significance of ...
November 15, 2011 (Orlando, Florida) — Final results of the AIM-HIGH trial appear to suggest that the signal of increased ischemic stroke with niacin, which was one of the reasons the study was stopped early, could have been the play of chance, with the final p value for ischemic ...
Dr William Boden (University of Buffalo, NY) discusses results from the AIM–HIGH trial and how extended-release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL cholesterol is optimally controlled with statin therapy with Dr Manesh Patel (Duke Clini...
: The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglyceride and Impact on Global Health Outcomes) Author links open overlay panelJohn J. Albers PhD ∗, April Slee MS †, Kevin D. O'Brien MD ‡, Jennifer G. Robinson MD MPH §, Moti L. ...
摘要: The article discusses the Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN) and the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL Cholesterol/High Triglyceride and Impact on Global Health Outcomes (AIM-HIGH) trial....
The AIM-HIGH trial is the first large outcome-driven trial of niacin versus placebo in the modern area. In this trial of patients with stable coronary heart disease and atherogenic dyslipidemia on statin +/− ezetimibe, the addition of niacin did not reduce major cardiovascular events compared ...
It was clearly a challenge to end the AIM-HIGH trial after a mean follow-up of 3 years. The rise in strokes may have been a chance finding because many of the participants assigned niacin who sustained a stroke had stopped their niacin a number of months ...